Sol-Gel Technologies Ltd. (SLGL): Shareholders' Equity
$22.81M
As of 2025-12-31
-18.5%
3-year compound annual growth
-14.8%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $22.81M | -20.9% | 2026-03-19, Balance as of period end |
| 2024-12-31 | $28.85M | -25.3% | 2026-03-19, Balance as of period end |
| 2023-12-31 | $38.64M | -8.5% | 2026-03-19, Balance as of period end |
| 2022-12-31 | $42.21M | -24.1% | 2025-04-29, Balance as of period end |
| 2021-12-31 | $55.59M | +9.3% | 2024-03-13, Balance as of period end |
| 2020-12-31 | $50.85M | -3.1% | 2023-03-10, Balance as of period end |
| 2019-12-31 | $52.47M | -17.9% | 2022-04-07, Balance as of period end |
| 2018-12-31 | $63.91M | n/m | 2021-03-04, Balance as of period end |
| 2017-12-31 | -$52.70M | n/m | 2020-03-24, Balance as of period end |
| 2016-12-31 | -$31.34M | n/m | 2019-03-21, Balance as of period end |
| 2015-12-31 | -$11.52M | n/a | 2018-03-26, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Sol-Gel Technologies Ltd. (SLGL) | 2025-12-31 | $22.81M | -20.9% |
| Evofem Biosciences, Inc. (EVFM) | 2025-12-31 | -$74.34M | n/m |
| Scynexis Inc (SCYX) | 2025-12-31 | $49.38M | -10.4% |
| CASI Pharmaceuticals, Inc. (CASIF) | 2025-12-31 | -$37.28M | n/m |
| NewAmsterdam Pharma Co N.V. (NAMS) | 2025-12-31 | $683.43M | -9.8% |
| uniQure N.V. (QURE) | 2025-12-31 | $198.90M | n/m |
| Alumis Inc. (ALMS) | 2025-12-31 | $301.30M | +15.8% |
| Entrada Therapeutics, Inc. (TRDA) | 2025-12-31 | $306.13M | -28.6% |
| Opus Genetics, Inc. (IRD) | 2025-12-31 | $15.35M | +128.3% |
Compare SLGL, EVFM, SCYX, CASIF side by side · Screen every company in Pharmaceutical Preparations ↗